Abstract
Objectives Microglia monitor and respond to the brain’s microenvironment to maintain homeostasis. However, in Alzheimer’s disease and related dementias (ADRD), microglia may contribute to pathology. We hypothesized that AD-related inflammatory changes, measured with TSPO PET, would be locally associated with amyloid, tau, and neurodegeneration, and influence key pathways among them.
Methods Participants (21 controls, 25 with ADRD) from the Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer’s Disease study underwent baseline amyloid PET (Florbetaben SUVR), tau PET (MK6240 SUVR), TSPO PET (ER176 SUVR), and structural MRI (gray matter volume). Cognitive assessments and consensus diagnoses (e.g., MCI, AD, PCA, FTD, LATE) were performed at the CUIMC ADRC with biomarker information when available. We evaluated regional colocalization of biomarker elevation in ADRD compared to controls, TSPO associations with ATN biomarkers, and TSPO mediations along key ATN pathways. Sensitivity analyses were stratified by amyloid positivity.
Results Elevated TSPO was spatially colocalized with elevated tau (8 regions), amyloid (7 regions), and neurodegeneration (4 regions). Higher TSPO in limbic, temporal, and parietal regions was associated with higher tau (0.8 to 2.3, p<0.03), which remained significant after adjusting for amyloid and neurodegeneration in the inferior parietal cortex. TSPO mediated the association between tau and neurodegeneration in limbic and temporal regions (−0.27 to -0.39, p<0.02; 43% to 89% of the total effect), while tau did not mediate the association between TSPO and neurodegeneration. TSPO also mediated the association between amyloid and tau, as well as tau across progressive Braak stages, but only in amyloid-positive ADRD.
Conclusion Across ADRD diagnoses with different underlying brain microenvironments (e.g., pathology/copathology) to which microglia are sensitive, higher microglia density was associated with greater tau burden and mediated tau-associated neurodegeneration. Glia may represent a promising target for intervention strategies in ADRD-associated tau and neurodegeneration.
Competing Interest Statement
WCK has a consulting agreement with Cerveau Technologies and an employee of Esai. SR is an employee of Life Molecular Imaging. However, Cerveau, Esai, and Life Molecular Imaging were not involved in the study design or interpretation of these results. WCK and SR contributed to the design, collection, and analysis of data while at Columbia University Irving Medical Center. No authors have conflicts of interest to report.
Clinical Trial
NCT04576793
Funding Statement
This work was funded by NIA R01 AG063888 and R00 AG065506, and is registered on ClinicalTrials.gov under NCT04576793. Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Number P30AG066462. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Columbia University Irving Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
